• Cancer Center Associates

New drug approval by FDA for MDS related anemia



On April 3, 2020, the Food and Drug Administration approved luspatercept-aamt (REBLOZYL) for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.


The main efficacy  was reported as the absence of any RBC transfusion during any consecutive 8-week period between Weeks 1 and 24.


Reblozyl was given once every 3 weeks by subcutaneous injection.



Amanullah Khan, MD, PhD.

President, Cancer Center Associates

Office Hours:

Monday - Friday: 8:00 am - 4:30 pm

Now offering Telemedicine 

New Patient?

Have an upcoming appointment? Please fill out this online assessment to save time on your visit.

Locations

4201 Medical Center Drive, Suite 180

McKinney, TX  75069

Phone: (972) 548-9690

Need to refill a Rx?

Running low on your prescription? Fill out the online request form. 

2698 N. Galloway, Suite 103

Mesquite, TX 75150

Phone: (972) 686-6646

5948  W. Parker Rd. Suite 100

Plano, TX  75093

Phone: (972) 686-6646

© 2020 CANCER CENTER ASSOCIATES.  ALL RIGHTS RESERVED.  Design by BigMagic.com